Intravitreal ranibizumab for myopic choroidal neovascularization: 12-Month Results

Retina

Volumn 30, Issue 3, 2010, Pages 407-412

  Silva, Rufino M ^a,b   Ruiz Moreno, José M ^c,d   Rosa, P ^e   Carneiro, Ângela ^f   Nascimento, João ^e   Rito, Luís F ^a   Cachulo, M Luz ^a,b   Carvalheira, F ^a,b,g   Murta, Joaquim N ^a,b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b Biomedical Research on Light and Image   (Portugal)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^d Alicante   (Spain)

^e Institute of Ophthalmology   (Portugal)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

^g Hospital Distrital   (Portugal)

Author keywords

Antiangiogenic drugs; Bevacizumab; CNV; Lucentis; Myopia; Photodynamic therapy; Ranibizumab; Verteporfin

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; MALE; METAMORPHOSIS; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; RETINA DETACHMENT; SUBRETINAL NEOVASCULARIZATION; THICKNESS; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 77949360576     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181c9691e     Document Type: Article

References (18)

1. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581.
2. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983;90:923-926.
3. Tabandeh H, Flynn HW Jr, Scott IU, et al., Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063-2067.
4. Yoshida T, Ohno-Matsui K, Ohtake Y, et al., Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002;109: 712-719.
5. Blinder KJ, Blumenkranz MS, Bressler NM, et al., Verteporfin therapy of subfoveal choroidal neovascularisation in pathologic myopia: 2-year results of a randomized clinical trial- VIP report no. 3. Ophthalmology 2003;110:667-673.
6. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003;87:173-176.
7. Pece A, Vadalà M, Isola V, Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2000;143:449-454.
8. Rich RM, Rosenfeld PJ, Puliafito CA, et al., Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
9. Ikuno YH, Sayanagi K, Soga K, et al., Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
10. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al., Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-712.
11. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al., Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye (Lond) 2009;23:334-338.
12. Rosenfeld PJ. Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br J Ophthalmol 2007;91:128-130.
13. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CA. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147:84-93.
14. Sakaguchi H, Ikuno Y, Gomi F, et al., Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165.
15. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization. Six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-2196.
16. Silva RM, Ruiz-Moreno JM, Nascimento J, et al., Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularisation. Retina 2008;28:1117-1123.
17. Tong JP, Chan WN, Liu DT, et al., Aqueous humor levels of vascular endothelial growth factor and pigment epitheliumderived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141:456-462.
18. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-372.